New Analyses of Phase 2 EQUATOR Clinical Program Support Durable Efficacy of Filgotinib in Psoriatic Arthritis
N/A
Provided Content: Content provided by Business Wire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
